2023-05-14T14:02:38-05:00 2022-12-31 111986323 MARCUM LLP 53 STATE STREET BOSTON MA 02109 990 2022-01-01 206745475 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION ADEN 7812489699 PO BOX 442 NEEDHAM MA 02494 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 7812489699 2023-05-12 1 JEFFREY KAUFMAN 999009999 0 KRISTEN CUMMINGS P01510495 6178075000 2023-05-12 0 AAL1 IAL1 2022 2023-04-26 12:10:37Z JEFFREY A KAUFMAN PO BOX 442 NEEDHAM MA 02494 1391687 0 X WWW.ACCRF.ORG X 2005 MA SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA. 9 7 2 0 0 0 1588834 807996 837896 551076 403 27583 0 0 2427133 1386655 696641 529854 0 0 284579 296319 0 0 15513 1089803 792023 2071023 1618196 356110 -231541 3133519 2659707 607759 136888 2525760 2522819 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE. 0 0 1050333 150000 551076 TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS. 457418 317712 0 BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEEL OF THE DISEASE. 1507751 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 14 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 MA NY CA CT FL MI NC NH NY OH PA VA X MARNIE A KAUFMAN 7814491757 60 SAVOY ROAD NEEDHAM MA 02492 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR/BOARD CHAIR 50.00 X X 150000 0 0 THOMAS DILENGE BOARD VICE CHAIR 5.00 X X 0 0 0 RALPH MOLLIS TREASURER 5.00 X X 0 0 0 MARNIE A KAUFMAN DIRECTOR & CFO 25.00 X 0 0 0 ELIZABETH WEHLAGE DIRECTOR 5.00 X 0 0 0 LISA BAKRI DIRECTOR 5.00 X 0 0 0 DAVID MORSE DIRECTOR 5.00 X 0 0 0 BOZHO TODORICH DIRECTOR 5.00 X 0 0 0 EMMA KINLOCH DIRECTOR 5.00 X 0 0 0 NICOLE SPARDY BURR DIRECTOR OF RESEARCH 50.00 X 124166 0 0 274166 0 0 2 0 0 0 0 807996 807996 RESEARCH STUDIES 621500 551076 551076 551076 11819 11819 20796 5032 15764 15764 15764 1386655 551076 0 27583 467712 467712 62142 62142 150000 109506 34944 5550 125531 91642 29244 4645 20788 15176 4843 769 20750 20750 2576 833 1743 37805 30681 4318 2806 2872 2872 3137 3137 RESEARCH STUDIES EXPENS 431586 431586 DRUG SCREENING EXPENSE 290642 290642 STATE REGISTRATION AND 2354 2354 OTHER FEES 301 301 1618196 1507751 94932 15513 352422 134305 2469188 2225840 297028 222684 14881 76878 3133519 2659707 175960 89190 400660 25000 31139 22698 607759 136888 X 2525760 2522819 2525760 2522819 3133519 2659707 -231541 228600 0 X 0 1 X 1 0 X 1809421 1833516 787706 1588834 807996 6827473 1809421 1833516 787706 1588834 807996 6827473 911765 5915708 21048 35299 10071 403 30851 97672 64692 100000 164692 7089837 0.83440 0.89000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1424155 37500 37500 1386655 0 1386655 1655696 37500 37500 1618196 0 1618196 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION. EXPLORATION OF THE IMMUNE MICRO-ENVIRONMENT OF ADENOID CYSTIC CARCINOMA USING MULTIPLEX IMMUNOHISTOCHEMISTRY 37142 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION. ACC PATIENT-DERIVED ORGANOIDS 25000 0 0 0 0 0 0 62142 0 62142 EUROPE (INCLUDING ICELAND & GREENLAND) EXPLORATION OF THE IMMUNE MICRO-ENVIRONMENT OF ADENOID CYSTIC CARCINOMA USING MULTIPLEX IMMUNOHISTOCHEMISTRY 37142 CHECK OR FUND TRANSFER 0 EAST ASIA AND THE PACIFIC ACC PATIENT-DERIVED ORGANOIDS 25000 CHECK OR FUND TRANSFER 0 2 0 0 0 0 0 0 PART I, LINE 2: ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS. PART III ACCOUNTING METHOD: 1 MD ANDERSON CANCER CENTER PO BOX 4486 HOUSTON TX 772104486 746001118 501(C)(3) 25000 0 SUPPORT FOR THE STUDY OF IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADENOID CYSTIC CARCINOMA UNIVERSITY OF CHICAGO 5235 S HARPER COURT 4TH FLOOR CHICAGO IL 60615 362177139 501(C)(3) 25000 0 SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC DANA-FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 25000 0 SUPPORT FOR THE STUDY OF DIRECT GENE-REGULATORY FUNCTIONS OF MYB/MYBL1 FUSION ONCOPROTEINS DANA-FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 25000 0 SUPPORT FOR THERAPEUTIC DRUG SCREENING USING A NOVEL IMPLANTABLE MICRODEVICE (IMD) IN ADENOID CYSTICCARCINOMA (ACC): A WINDOW OF OPPORTUNITY STUDY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET SUITE 540 BOSTON MA 02114 041564655 501(C)(3) 25000 0 SUPPORT FOR MGH ACC CLINICAL DATABASE DANA-FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 242712 0 SUPPORT FOR THE STUDY OF TARGETED PROTEIN DEGRADATION APPROACHES TO DEFINE THE MOLECULAR MECHANISMS OF MYB ONCOPROTEINS IN ACC JOHN HOPKINS UNIVERSITY 3910 KESWICK ROAD SUITE N2100 BALTIMORE MD 21211 520595110 501(C)(3) 100000 0 SUPPORT FOR A PHASE 2, SINGLE-ARM, MULTI-CENTER STUDY OF 177LU-PSMA (177LU-PNT2002) IN PATIENTS WITH PSMA-POSITIVE ADENOID CYSTIC CARCINOMA 5 PART I, LINE 2: ACCRF TYPICALLY REQUIRES INTERIM REPORTING ON RESEARCH PROJECTS EVERY SIX MONTHS AS WELL AS A FINAL REPORT FOLLOWING PROJECT COMPLETION. PART I, LINE 2: ACCRF TYPICALLY REQUIRES INTERIM REPORTING ON RESEARCH PROJECTS EVERY SIX MONTHS AS WELL AS A FINAL REPORT FOLLOWING PROJECT COMPLETION. PART II, LINE 1, COLUMN (H): NAME OF GOVERNMENT OR ORGANIZATION: M.D. ANDERSON CANCER CENTER (H) PURPOSE OF GRANT OR ASSISTANCE: SUPPORT FOR THE STUDY OF IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADNEOID CYSTIC CARCINOMA PART II, LINE 1, COLUMN (H): NAME OF GOVERNMENT OR ORGANIZATION: UNIVERSITY OF CHICAGO (H) PURPOSE OF GRANT OR ASSISTANCE: SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC PART II, LINE 1, COLUMN (H): NAME OF GOVERNMENT OR ORGANIZATION: DANA-FARBER (H) PURPOSE OF GRANT OR ASSISTANCE: SUPPORT FOR THE STUDY OF DIRECT GENE-REGULATORY FUNCTIONS OF MYB/MYBL1 FUSION ONCOPROTEINS PART II, LINE 1, COLUMN (H): NAME OF GOVERNMENT OR ORGANIZATION: DANA-FARBER/BWH/HARVARD (H) PURPOSE OF GRANT OR ASSISTANCE: SUPPORT FOR THERAPEUTIC DRUG SCREENING USING A NOVEL IMPLANTABLE MICRODEVICE (IMD) IN ADENOID CYSTICCARCINOMA (ACC): A WINDOW OF OPPORTUNITY STUDY PART II, LINE 1, COLUMN (H): NAME OF GOVERNMENT OR ORGANIZATION: MASS GENERAL HOSPITAL (H) PURPOSE OF GRANT OR ASSISTANCE: SUPPORT FOR MGH ACC CLINICAL DATABASE FORM 990, PART VI, SECTION A, LINE 2 THE EXECUTIVE DIRECTOR, JEFFREY A. KAUFMAN, IS MARRIED TO A DIRECTOR ON THE BOARD, MARNIE A. KAUFMAN. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY MANAGEMENT. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL DIRECTORS. THE DIRECTORS ARE ASKED IF THEY HAVE ANY QUESTIONS OR COMMENTS AND A GENERAL REVIEW OF THE FORM IS CONDUCTED BY MANAGEMENT . REVISIONS AND CORRECTIONS ARE MADE AS NECESSARY. SUBSEQUENTLY, THE FORM IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C A FORMAL PROCESS IS UNDERTAKEN EACH YEAR TO MONITOR AND ENFORCE THE CONFLICT OF INTEREST POLICY CONTAINED WITHIN THE BYLAWS . EACH JANUARY, AN ANNUAL SURVEY ON CONFLICTS OF INTEREST IS COMPLETED BY EVERY DIRECTOR AND OFFICER COVERING THE PRIOR CALENDAR YEAR. ALL BUSINESS RELATIONSHIPS, IF ANY, ARE REPORTED TO THE BOARD OF DIRECTORS. EXCLUDING ANY INTERESTED PARTIES, A MAJORITY OF REMAINING DIRECTORS DETERMINES WHETHER A CONFLICT OF INTEREST HAS OCCURRED AND WHETHER A MORE ADVANTAGEOUS TRANSACTION IS AVAILABLE TO THE FOUNDATION THAT WOULD NOT LEAD TO A CONFLICT OF INTEREST. THE BOARD IS CHARGED WITH TAKING APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION IN THE CASE OF A VIOLATION OF THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15A A FORMAL STRATEGIC REVIEW, OBJECTIVE SETTING AND PERFORMANCE REVIEW PROCESS IS UNDERTAKEN EACH YEAR. THE BOARD OF DIRECTORS REVIEWS THE PERFORMANCE OF THE ORGANIZATION AND EXECUTIVE DIRECTOR, BASED ON GOALS AND OBJECTIVES PREVIOUSLY AGREED UPON DURING THE PRIOR CALENDAR YEAR AND ON A PERFORMANCE REPORT SUBMITTED BY THE EXECUTIVE DIRECTOR IN ADVANCE. THE INDEPENDENT DIRECTORS OF THE BOARD MEET SEPARATELY TO ASSESS THE EXECUTIVE DIRECTOR'S PERFORMANCE, AGREE ON A PROCESS TO INFORM THE EXECUTIVE DIRECTOR OF ANY AREAS OF NEEDED IMPROVEMENT, AND AGREE UPON A MERIT AND/OR COST OF LIVING SALARY INCREASE FOR THE DIRECTOR , SUBJECT TO AVAILABILITY OF FUNDS AND MAINTENANCE OF AN APPROPRIATE RATIO BETWEEN SUCH SALARY AND ACCRF FUNDRAISING/REVENUE TOTALS IN ANY GIVEN YEAR . THE BOARD OF DIRECTORS SETS PERFORMANCE OBJECTIVES AND METRICS FOR THE ORGANIZATION AND THE EXECUTIVE DIRECTOR FOR THE CURRENT CALENDAR YEAR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS (ARTICLES OF INCORPORATION AND BY-LAWS}, ITS CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. THE ORGANIZATION WILL MAIL COPIES UPON REQUEST OR PROVIDE COPIES TO THOSE WHO COME TO THE ADMINISTRATIVE OFFICES DURING NORMAL BUSINESS HOURS.